Drugs / Pepinemab
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05378464 | May 2022 → Aug 2026 | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03769155 | Dec 2018 → Dec 2023 overdue | cutaneous melanoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03690986 | Nov 2018 → Apr 2027 expected | head and neck squamous cell carcinoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03425461 | Jun 2018 → Mar 2021 | cutaneous melanoma, metastatic melanoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03373188 | Dec 2017 → Oct 2021 | colorectal adenocarcinoma, metastasis from malignant tumor of colon, pancreatic adenocarcinoma | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01764737 | Dec 2012 → Nov 2014 | multiple sclerosis | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01313065 | Jan 2011 → Jun 2014 | cancer | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 1/25 trials · 1 met primary | ||||||
| Phase 1/2 | NCT05102721 | Dec 2022 → Dec 2028 expected | pancreatic adenocarcinoma | Vaccinex Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04815720 | Aug 2021 → Jul 2024 | head and neck squamous cell carcinoma | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04381468 | Jul 2021 → Jun 2024 | Alzheimer disease | Vaccinex Inc. | Completed | Met primary |
| Phase 1/2 | NCT03320330 | Jan 2018 → Dec 2020 | bone osteosarcoma, refractory malignant neoplasm, secondary malignant neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT03268057 | Oct 2017 → Sep 2020 | non-small cell lung carcinoma | Vaccinex Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02481674 | Jul 2015 → Aug 2020 | Huntington disease | Vaccinex Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-10-07 | Vaccinex Inc. | Results SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study vaccinex.com ↗
The predefined primary biomarker endpoint was met; the trial was not powered to establish clinical efficacy. |
| 2025-12-03 | Vaccinex Inc. | Results Vaccinex Provides Update on Biomarkers Associated with Response to Treatment of Early Stage AD with Pepinemab at CTAD (Clinical Trials on Alzheimer's Disease) vaccinex.com ↗ |
| 2025-05-27 | Vaccinex Inc. | Results Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting vaccinex.com ↗
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. |
| 2025-04-21 | Vaccinex Inc. | Results Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) vaccinex.com ↗
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. |
| 2024-11-05 | Vaccinex Inc. | Results Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting vaccinex.com ↗
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. |
| 2024-10-31 | Vaccinex Inc. | Results Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain vaccinex.com ↗
We report today that expression of plasma GFAP and p-tau 217 biomarkers appears to increase predominantly during MCI and that this is inhibited by pepinemab treatment. |
| 2024-08-14 | Vaccinex Inc. | Results Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership vaccinex.com ↗
Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. |
| 2024-07-31 | Vaccinex Inc. | Results Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease vaccinex.com ↗
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering treatment of Alzheimer’s disease (AD) with anti-Semaphorin 4D (SEMA4D) antibody, today announced positive results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD. |
| 2023-10-26 | Vaccinex Inc. | Results Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases vaccinex.com ↗
Importantly, results from a highly sensitive S-PLEX GFAP immunoassay demonstrated a significant reduction in plasma GFAP levels in HD patients treated with pepinemab compared to those receiving placebo. |
All press releases naming this drug 14 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pepinemab | “VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg.” NCT02481674 ↗ |
| Known as | Anti-sema4d monoclonal antibody vx15/2503 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297884 ↗ |
| Known as | moAb VX15/2503 | “moAb VX15/2503” NCT03425461 ↗ |
| Known as | VX-15 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297884 ↗ |
| Known as | VX15/2503 | “VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg.” NCT02481674 ↗ |
| Action | Inhibit | “antibody neutralization of SEMA4D may represent a new therapeutic strategy” NCT01764737 ↗ |
| Modality | Monoclonal antibody | “The study drug, VX15/2503, is a monoclonal antibody that binds to the semaphorin 4D (SEMA4D; CD100) antigen.” NCT01313065 ↗ |
| Route | Intravenous | “to be administered intravenously” NCT01313065 ↗ |
| Target | SEMA4D | “binds to the semaphorin 4D (SEMA4D; CD100) antigen” NCT01313065 ↗ |